Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Mizoribine: a new approach in the treatment of renal disease Kawasaki YClin Dev Immunol 2009[]; 2009 (ä): 681482Mizoribine (MZB) is an imidazole nucleoside and an immunosuppressive agent. The immunosuppressive effect of MZB has been reported to be due to the inhibition of DNA synthesis in the S phase of the cell cycle. Because of its relative lack of toxicity, during the past decade MZB has been frequently used instead of azathioprine as a component of immunosuppressive drug regimens. MZB is being used to treat renal transplantation patients, IgA nephropathy, lupus erythematosus, and childhood nephrotic syndrome (NS), and some recent studies have assessed the efficacy of oral MZB pulse therapy for severe lupus nephritis, steroid-resistant NS, and frequently relapsing-steroid-dependent NS. This review summarizes the published findings on the efficacy of MZB for renal disease including IgA nephropathy, lupus nephritis, and NS, as well as of oral MZB pulse therapy for severe lupus nephritis and NS, and also the mechanism of the effect of oral MZB pulse therapy on the lymphocyte cell cycle.|*Immunosuppressive Agents/administration & dosage/adverse effects/pharmacokinetics/therapeutic use[MESH]|Adolescent[MESH]|Adult[MESH]|Child[MESH]|Female[MESH]|Glomerulonephritis, IGA/drug therapy[MESH]|Humans[MESH]|IMP Dehydrogenase/*antagonists & inhibitors[MESH]|Kidney Diseases/*drug therapy[MESH]|Lupus Nephritis/drug therapy[MESH]|Middle Aged[MESH]|Nephrotic Syndrome/drug therapy[MESH]|Ribonucleosides/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use[MESH]|Treatment Outcome[MESH] |
